3728 Jinke Rd, Building 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience's KRAS G12D Inhibitor TSN1611 Selected for 2026 ASCO Rapid Oral Abstract Session
The latest Phase I/II clinical data for TSN1611, an oral KRAS G12D inhibitor independently developed by Tyligand Bioscience, has been officially selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and will be presented in a "Rapid Oral Abstract Session". This presentation will highlight the latest efficacy and safety data of TSN1611 in patients with metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation. Details of the session are as follows:
-
Abstract Number: 8516
-
Session: Rapid Oral Abstract Session - Lung Cancer - Metastatic Non-Small Cell Lung Cancer
-
Session Time: May 30, 2026, 1:15 PM - 2:45 PM (CDT)
KRAS G12D is currently one of the most challenging oncogenic driver mutations in the field of solid tumors, holding significant clinical relevance in various malignancies including NSCLC, pancreatic cancer, and colorectal cancer. As the global research and development of KRAS-targeted therapies continue to evolve towards more precise inhibition and combination strategies, innovative therapies targeting KRAS G12D are gaining widespread attention.
As a new-generation oral KRAS G12D inhibitor independently developed by Tyligand Bioscience, TSN1611 has demonstrated clinically meaningful antitumor activity and a favorable safety profile in patients with various solid tumors, including NSCLC. Its selection for the ASCO Rapid Oral Abstract Session reflects the international oncology community's interest in the clinical progress of TSN1611 and further validates Tyligand Bioscience's innovative R&D capabilities in the field of KRAS-targeted therapy.
Tyligand Bioscience will continue to advance the clinical development of TSN1611 and actively explore its potential in different tumor types and combination treatment regimens, aiming to provide more innovative treatment options for patients with KRAS G12D mutations.
Tyligand Bioscience is a clinical-stage biotech company founded in 2017, focusing on the discovery and development of innovative cancer therapeutics. The company commenced business operations in 2018. Leveraging decades of profound experience in leading drug discovery and development at multinational pharmaceutical companies, the management team has successfully established technology platforms with fully integrated capabilities across small molecules and antibody-drug conjugates (ADCs). Serving as an innovation engine, these platforms have enabled the company to build a diversified pipeline encompassing multiple drug candidates.
Consistently driven by the mission to address significant unmet clinical needs, Tyligand Bioscience is dedicated to becoming a leading global biopharmaceutical enterprise. By continuously delivering high-quality, differentiated innovative therapies, the company aims to improve the quality of life for patients worldwide and create long-term commercial value.
For more info about Tyligand Bioscience, please visit www.tyligand.com
- Tyligand Bioscience